Toward The Global Big Pharma League: Yuhan’s Ambitions After Leclaza
Looking To Transcend Korean Pharma's Limits
With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.
